{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:00:31Z","timestamp":1794027631270,"version":"4.8.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["#2020-02014"],"award-info":[{"award-number":["#2020-02014"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["#2022-01428"],"award-info":[{"award-number":["#2022-01428"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-01472"],"award-info":[{"award-number":["2022-01472"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2020-06101"],"award-info":[{"award-number":["2020-06101"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["#2022-01018"],"award-info":[{"award-number":["#2022-01018"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["#2019-02397"],"award-info":[{"award-number":["#2019-02397"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009240","name":"Swedish Association of Local Authorities and Regions","doi-asserted-by":"publisher","award":["#FoUI-975207"],"award-info":[{"award-number":["#FoUI-975207"]}],"id":[{"id":"10.13039\/501100009240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["#2021-02680"],"award-info":[{"award-number":["#2021-02680"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KI Foundations"},{"DOI":"10.13039\/501100000942","name":"Brain Foundation","doi-asserted-by":"publisher","award":["#FO2021-0331"],"award-info":[{"award-number":["#FO2021-0331"]}],"id":[{"id":"10.13039\/501100000942","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Erling-Persson Foundation"},{"name":"Center for Innovative Medicine Foundation","award":["#FoUI-963369"],"award-info":[{"award-number":["#FoUI-963369"]}]},{"name":"\u00c5ke Wibergs Foundation","award":["#M22-0170"],"award-info":[{"award-number":["#M22-0170"]}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["#2022-01631"],"award-info":[{"award-number":["#2022-01631"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["987010"],"award-info":[{"award-number":["987010"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation for Geriatric Diseases at Karolinska Institutet","award":["2022-01278"],"award-info":[{"award-number":["2022-01278"]}]},{"name":"Region Stockholm Clinical Appointment","award":["988371"],"award-info":[{"award-number":["988371"]}]},{"DOI":"10.13039\/501100003793\"","name":"Swedish Heart-Lung Foundation","doi-asserted-by":"publisher","award":["20220524"],"award-info":[{"award-number":["20220524"]}],"id":[{"id":"10.13039\/501100003793\"","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793\"","name":"Swedish Heart-Lung Foundation","doi-asserted-by":"publisher","award":["20190322"],"award-info":[{"award-number":["20190322"]}],"id":[{"id":"10.13039\/501100003793\"","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["101053962"],"award-info":[{"award-number":["101053962"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish State Support for Clinical Research","award":["#ALFGBG-71320"],"award-info":[{"award-number":["#ALFGBG-71320"]}]},{"DOI":"10.13039\/100002565","name":"Alzheimer Drug Discovery Foundation","doi-asserted-by":"crossref","award":["#201809-2016862"],"award-info":[{"award-number":["#201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AD Strategic Fund and the Alzheimer's Association","award":["#ADSF-21-831376-C"],"award-info":[{"award-number":["#ADSF-21-831376-C"]}]},{"name":"AD Strategic Fund and the Alzheimer's Association","award":["#ADSF-21-831381-C"],"award-info":[{"award-number":["#ADSF-21-831381-C"]}]},{"name":"AD Strategic Fund and the Alzheimer's Association","award":["#ADSF-21-831377-C"],"award-info":[{"award-number":["#ADSF-21-831377-C"]}]},{"DOI":"10.13039\/501100021720","name":"Olav Thon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Erling-Persson Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["#FO2022-0270"],"award-info":[{"award-number":["#FO2022-0270"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["JPND2021-00694"],"award-info":[{"award-number":["JPND2021-00694"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012621","name":"University College London Hospitals Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cholinesterase inhibitors (ChEIs) are the first-line symptomatic pharmacologic treatment for patients with mild-to-moderate Alzheimer's disease (AD). Although the target organ for this group of drugs is the brain, inhibition of the enzyme may affect cardiac function through vagotonic and anti-inflammatory effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the impact of ChEIs on outcomes in patients with AD who have experienced myocardial infarction (MI) prior to the AD diagnosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients who had experienced MI before they were diagnosed with AD or Alzheimer's mixed dementia between 2008 and 2018 were identified from the Swedish Dementia Registry (SveDem, www.svedem.se), which was linked to the National Patient Registry to obtain data on MI and mortality. Cox proportional hazards regression model among a propensity score-matched dataset was performed to assess the association between ChEI treatment and clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 3198 patients with previous MI and a diagnosis of AD or mixed dementia, 1705 (53%) were on treatment with ChEIs. Patients treated with ChEIs were more likely to be younger and have a better overall cardiovascular (CV) risk profile. The incidence rate of all-cause death (per 1000 patient-years) in the propensity-matched cohort of 1016 ChEI users and 1016 non-users was 168.6 in patients on treatment with ChEIs compared with 190.7 in patients not on treatment with ChEIs. In this propensity-matched cohort, treatment with ChEIs was associated with a significantly lower risk of all-cause death (adjusted hazard ratio 0.81, 95% confidence interval 0.71\u20130.92) and a greater reduction with higher doses of ChEIs. While in the unadjusted analysis, ChEIs were associated with a lower risk of both CV and non-CV death, only the association with non-CV death remained significant after accounting for baseline differences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment with ChEIs was associated with a significantly reduced risk of all-cause death, driven by lower rates of non-CV death in a nationwide cohort of patients with previous MI and a diagnosis of AD or mixed dementia. These associations were greater with higher ChEI doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Condensed Abstract<\/jats:title>\n                  <jats:p>We assessed the association between cholinesterase inhibitors (ChEIs) and clinical outcomes in a nationwide cohort of patients with previous myocardial infarction (MI) and a diagnosis of Alzheimer's disease (AD) or mixed dementi. In propensity-matched analysis, treatment with ChEIs was associated with a 19% reduction in all-cause death driven by non-cardiovascular death. The reduction in all-cause death was greater with the higher doses of ChEIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvad102","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T09:22:45Z","timestamp":1705310565000},"page":"128-136","source":"Crossref","is-referenced-by-count":16,"title":["Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5688-6101","authenticated-orcid":false,"given":"Bahira","family":"Shahim","sequence":"first","affiliation":[{"name":"Heart, Vascular and Neuro Theme, Karolinska University Hospital , 17177 Stockholm , Sweden"},{"name":"Department of Medicine Solna, Karolinska Institutet , 17177 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-3431","authenticated-orcid":false,"given":"Hong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet , 17177 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Haugaa","sequence":"additional","affiliation":[{"name":"Heart, Vascular and Neuro Theme, Karolinska University Hospital , 17177 Stockholm , Sweden"},{"name":"Department of Medicine Solna, Karolinska Institutet , 17177 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg , 41345 M\u00f6lndal , Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , 41345 M\u00f6lndal , Sweden"},{"name":"UK Dementia Research Institute at UCL , London , UK"},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology , London , UK"},{"name":"Hong Kong Center for Neurodegenerative Diseases , Hong Kong SAR , China"},{"name":"Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison , Madison, WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Jurga","sequence":"additional","affiliation":[{"name":"Heart, Vascular and Neuro Theme, Karolinska University Hospital , 17177 Stockholm , Sweden"},{"name":"Department of Medicine Solna, Karolinska Institutet , 17177 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Religa","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet , 17177 Stockholm , Sweden"},{"name":"Theme Inflammation and Aging, Karolinska University Hospital , Huddinge , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Eriksdotter","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet , 17177 Stockholm , Sweden"},{"name":"Theme Inflammation and Aging, Karolinska University Hospital , Huddinge , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"2024022306032089900_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(04)15900-X","article-title":"Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins","volume":"363","author":"Casserly","year":"2004","journal-title":"Lancet"},{"key":"2024022306032089900_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JAD-2010-090871","article-title":"Sharing pathogenetic mechanisms between acute myocardial infarction and Alzheimer's disease as shown by partially overlapping of gene variant profiles","volume":"23","author":"Licastro","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"2024022306032089900_bib3","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2024022306032089900_bib4","doi-asserted-by":"crossref","first-page":"e13396","DOI":"10.1111\/apha.13396","article-title":"The effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure: from cells to patient reports","volume":"228","author":"Khuanjing","year":"2020","journal-title":"Acta Physiol"},{"key":"2024022306032089900_bib5","doi-asserted-by":"crossref","first-page":"13687","DOI":"10.1038\/s41598-017-14021-8","article-title":"Cholinergic stimulation improves oxidative stress and inflammation in experimental myocardial infarction","volume":"7","author":"Bezerra","year":"2017","journal-title":"Sci Rep"},{"key":"2024022306032089900_bib6","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1253\/circj.CJ-13-0476","article-title":"Donepezil markedly improves long-term survival in rats with chronic heart failure after extensive myocardial infarction","volume":"77","author":"Li","year":"2013","journal-title":"Circ J"},{"key":"2024022306032089900_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3892\/ijmm.2013.1546","article-title":"Huperzine A ameliorates damage induced by acute myocardial infarction in rats through antioxidant, anti-apoptotic and anti-inflammatory mechanisms","volume":"33","author":"Sui","year":"2014","journal-title":"Int J Mol Med"},{"key":"2024022306032089900_bib8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/nbt.3663","article-title":"Blood pressure regulation by CD4(+) lymphocytes expressing choline acetyltransferase","volume":"34","author":"Olofsson","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2024022306032089900_bib9","doi-asserted-by":"crossref","first-page":"e2212476120","DOI":"10.1073\/pnas.2212476120","article-title":"Cholinergic regulation of vascular endothelial function by human ChAT(+) T cells","volume":"120","author":"Tarnawski","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024022306032089900_bib10","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","article-title":"The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease","volume":"34","author":"Nordstr\u00f6m","year":"2013","journal-title":"Eur Heart J"},{"key":"2024022306032089900_bib11","doi-asserted-by":"crossref","first-page":"15451","DOI":"10.1038\/srep15451","article-title":"Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"2024022306032089900_bib12","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/jgs.15415","article-title":"Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: a meta-analysis and systematic review","volume":"66","author":"Isik","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"2024022306032089900_bib13","doi-asserted-by":"crossref","first-page":"613979","DOI":"10.3389\/fimmu.2021.613979","article-title":"The cholinergic drug galantamine alleviates oxidative stress alongside anti-inflammatory and cardio-metabolic effects in subjects with the metabolic syndrome in a randomized trial","volume":"12","author":"Sangaleti","year":"2021","journal-title":"Front Immunol"},{"key":"2024022306032089900_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1567205043332009","article-title":"Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease\u2014from basic research to bedside","volume":"1","author":"Masuda","year":"2004","journal-title":"Curr Alzheimer Res"},{"key":"2024022306032089900_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/phrs.2001.0835","article-title":"Muscarinic receptors in the mammalian heart","volume":"44","author":"Dhein","year":"2001","journal-title":"Pharmacol Res"},{"key":"2024022306032089900_bib16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","article-title":"Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study","volume":"169","author":"Gill","year":"2009","journal-title":"Arch Intern Med"},{"key":"2024022306032089900_bib17","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/j.1532-5415.2009.02488.x","article-title":"Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system","volume":"57","author":"Hernandez","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"2024022306032089900_bib18","doi-asserted-by":"crossref","first-page":"e1000157","DOI":"10.1371\/journal.pmed.1000157","article-title":"Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study","volume":"6","author":"Park-Wyllie","year":"2009","journal-title":"PLoS Med"},{"key":"2024022306032089900_bib19","first-page":"e274","article-title":"Representation of patients with dementia in clinical trials of donepezil","volume":"11","author":"Gill","year":"2004","journal-title":"Can J Clin Pharmacol"},{"key":"2024022306032089900_bib20","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/ije\/30.suppl_1.S30","article-title":"A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden","volume":"30","author":"Hammar","year":"2001","journal-title":"Int J Epidemiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad102\/55974049\/pvad102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/2\/128\/56714923\/pvad102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/2\/128\/56714923\/pvad102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T06:09:45Z","timestamp":1708668585000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/2\/128\/7542308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,15]]},"published-print":{"date-parts":[[2024,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad102","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,1,15]]}}}